Next Article in Journal
Pigeons: A Novel GUI Software for Analysing and Parsing High Density Heterologous Oligonucleotide Microarray Probe Level Data
Next Article in Special Issue
Molecular Diagnostic Applications in Colorectal Cancer
Previous Article in Journal
Chromosomal Microarrays in Prenatal Diagnosis: Time for a Change of Policy?
Previous Article in Special Issue
From High-Throughput Microarray-Based Screening to Clinical Application: The Development of a Second Generation Multigene Test for Breast Cancer Prognosis
Article Menu

Export Article

From the third issue of 2017, Microarrays has changed its name to High-Throughput.

Open AccessReview
Microarrays 2013, 2(4), 318-339;

Lung Cancer Gene Signatures and Clinical Perspectives

Unit Cancer Genome Research, German Cancer Research Center and National Center for Tumor Diseases, Heidelberg 69120, Germany
Translational Lung Research Center Heidelberg (TLRC-H), German Center for Lung Research, Heidelberg 69120, Germany 
Received: 16 October 2013 / Revised: 19 November 2013 / Accepted: 6 December 2013 / Published: 13 December 2013
(This article belongs to the Special Issue Clinical Applications of Microarrays)
Full-Text   |   PDF [212 KB, uploaded 13 December 2013]


Microarrays have been used for more than two decades in preclinical research. The tumor transcriptional profiles were analyzed to select cancer-associated genes for in-deep functional characterization, to stratify tumor subgroups according to the histopathology or diverse clinical courses, and to assess biological and cellular functions behind these gene sets. In lung cancer—the main type of cancer causing mortality worldwide—biomarker research focuses on different objectives: the early diagnosis of curable tumor diseases, the stratification of patients with prognostic unfavorable operable tumors to assess the need for further therapy regimens, or the selection of patients for the most efficient therapies at early and late stages. In non-small cell lung cancer, gene and miRNA signatures are valuable to differentiate between the two main subtypes’ squamous and non-squamous tumors, a discrimination which has further implications for therapeutic schemes. Further subclassification within adenocarcinoma and squamous cell carcinoma has been done to correlate histopathological phenotype with disease outcome. Those tumor subgroups were assigned by diverse transcriptional patterns including potential biomarkers and therapy targets for future diagnostic and clinical applications. In lung cancer, none of these signatures have entered clinical routine for testing so far. In this review, the status quo of lung cancer gene signatures in preclinical and clinical research will be presented in the context of future clinical perspectives. View Full-Text
Keywords: lung cancer; NSCLC; biomarker; gene signature; testing lung cancer; NSCLC; biomarker; gene signature; testing
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Kuner, R. Lung Cancer Gene Signatures and Clinical Perspectives. Microarrays 2013, 2, 318-339.

Show more citation formats Show less citations formats

Article Metrics

Article Access Statistics



[Return to top]
Microarrays EISSN 2076-3905 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top